Theophylline ER

Class
Bronchodilators
Subclass
Nonselective phosphodiesterase inhibitors
Substance name
Theophylline, 1, 3-dimethylxanthine ER
Brand names
Theo-24®
Common formulations
Capsule
See also
Theophylline (Elixophyllin®, Uniphyl®)
Dosage and administration
Adults patients
Symptomatic relief
Reversible airway obstruction in patients with asthma
•
Start at: 300-400 mg PO daily, in divided doses, for 3 days
•
Maintenance: 400-600 mg PO daily, in divided doses
The second dose taken 10-12 hours after the morning dose and before the evening meal.
Reversible airway obstruction in patients with COPD
•
Start at: 300-400 mg PO daily, in divided doses, for 3 days
•
Maintenance: 400-600 mg PO daily, in divided doses
The second dose taken 10-12 hours after the morning dose and before the evening meal.
Treatment
Treatment of central sleep apnea in patients with high-altitude periodic breathing • Off-label
•
300 mg PO daily
Other off-label uses
•
Treatment of central sleep apnea in patients with HF
Indications for use
Labeled indications
Adults
•
Symptomatic relief of reversible airway obstruction in patients with asthma
•
Symptomatic relief of reversible airway obstruction in patients with COPD
•
Treatment of bradycardia in patients with SND
Off-label indications
Adults
•
Treatment of central sleep apnea in patients with HF
•
Treatment of central sleep apnea in patients with high-altitude periodic breathing
Safety risks
Contraindications
Hypersensitivity to theophylline or its components
Warnings and precautions
Exacerbation of cardiac arrhythmias
•
Use extreme caution in patients with cardiac arrhythmias (not including bradyarrhythmias).
Exacerbation of peptic ulcer disease
•
Use extreme caution in patients with active peptic ulcer disease.
Increased theophylline levels
•
Use caution in patients with acute pulmonary edema, congestive HF, cor pulmonale, high and/or prolonged fever, hypothyroidism, liver disease, renal impairment, sepsis with multi-organ failure, shock, or cessation of smoking, as well as in the elderly.
Seizure
•
Use extreme caution in patients with seizure disorders.
Specific populations
Renal impairment
eGFR ≥ 15 mL/min/1.73 m²
•
Use acceptable. No dose adjustment required.
eGFR < 15 mL/min/1.73 m²
•
Use with caution. Monitor serum concentrations.
Renal replacement therapy
Continuous renal replacement
•
Use acceptable. No dose adjustment required.
Intermittent hemodialysis
•
Use with caution. Administer the dose after dialysis session.
Peritoneal dialysis
•
Use with caution.
Hepatic impairment
Any severity
•
Use with caution. Reduce dose. Monitor serum concentrations.
Pregnancy and breastfeeding
Pregnancy
All trimesters • Australia Category: A
•
Generally acceptable for use. Evidence of fetal harm in animals. The 2020 ERS/TSANZ task force statement suggests that theophylline is compatible with pregnancy.
Breastfeeding
Acceptable for use during breastfeeding.
•
The 2020 ERS/TSANZ task force statement suggests that theophylline is compatible with breastfeeding.
Low excretion in breastmilk (5-25%).
Unknown drug levels in breastfed infants.
May potentially cause adverse effects in breastfed infants.
Adverse reactions
Unknown frequency
•
Peptic ulcer disease, intracranial hemorrhage, Stevens-Johnson syndrome, tachycardia, ↑ urine free cortisol, ↑ blood glucose, ↑ serum total cholesterol, ↓ serum free T3, ↑ serum uric acid, diarrhea, nausea, vomiting, dizziness, headache, insomnia, seizure, tremor, stuttering, irritability, restlessness, fever
Interactions
Drug(s)
Check Interactions
Reset

What did you think about this content?

Create free account

Sign up for free to access the full drug resource